Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054519 · ClinicalTrials.gov registry record · Phase 3
Improve PAD PERformance With METformin
A Phase 3 study of Peripheral Artery Disease, sponsored by Northwestern University.
- Active
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
- 5
- Study locations
NCT03054519: Active Phase 3 study of Peripheral Artery Disease, sponsored by Northwestern University.
NCT03054519 is a Phase 3 study of Peripheral Artery Disease that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 203 participants, above the 123-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (65% higher). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03054519, a Phase 3 study of Peripheral Artery Disease, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
- 5
- Study locations
Study Summary
The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.
Primary Outcome
Participants walking up and down a 100 foot hallway for six minutes following a standardized protocol. The goal is for them to walk as far as possible in six minutes
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
Study Locations (5)
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Louisiana
- Tulane University - New Orleans
- Ochsner Medical Center - New Orleans
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2025-11 |
| Phase | Phase 3 |
What the registry record for NCT03054519 still lists
NCT03054519 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, above the 123-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (65% higher).
The record links to 1 condition, with Peripheral Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03054519 lists 5 locations in 3 states (Illinois, Louisiana, Florida).
Frequently Asked Questions
What is clinical trial NCT03054519 about?
NCT03054519 is a clinical study titled "Improve PAD PERformance With METformin". The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.
What is the current status of trial NCT03054519?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2017-05-23. Estimated completion is 2025-11.
What conditions does trial NCT03054519 study?
This clinical trial studies the following conditions: Peripheral Artery Disease.
What interventions are being tested in trial NCT03054519?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT03054519?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03054519 being conducted?
This trial has 5 study locations across Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03054519's enrollment target sits among peer trials
203 13th of 50 higher than 38 of 50 other Peripheral Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
The COCOA-PAD II Trial
RECRUITING · Phase 3
-
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
RECRUITING · Phase 3
-
Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
COMPLETED · Phase 3
-
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
COMPLETED · Phase 3
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI